지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.10
- 수록면
- 1,130 - 1,137 (8page)
- DOI
- 10.4143/crt.2021.1103
이용수
초록· 키워드
오류제보하기
Purpose Trastuzumab has markedly improved the survival outcomes of patients with human epidermal growth factor receptor 2 (HER2)–positive breast cancer, and dual blockade of HER2 using trastuzumab and pertuzumab in combination with taxanes (THP) has become a standard of care for HER2-positive metastatic breast cancer (MBC) worldwide since the CLEOPATRA trial. We assessed the outcomes of THP as a first-line treatment for Korean HER2-positive MBC patients in the real-world setting.Materials and Methods Between August 2008 and October 2020, we identified 228 HER2-positive MBC patients who received THP as a first-line palliative chemotherapy. We analyzed survival outcomes, efficacy, and adverse events of THP retrospectively.Results After a median follow-up duration of 28.7 months, median overall survival and progression-free survival were 58.3 months (95% confidence interval [CI], 36.6 to 80.0) and 19.1 months (95% CI, 16.2 to 21.9), respectively. Better survival outcomes were observed in patient who received docetaxel for more than six cycles. Patients exposed to anti-HER2 directed therapies in a perioperative setting had poor survival outcomes. The overall response rate was 86.8% with a complete response (CR) rate of 17.7%. Among responders, 16.7% of patients sustained THP over 35 months and showed better survivals and higher CR rates. Adverse events were comparable to those reported in previous studies.Conclusion In a real-world context, clinical outcomes of Korean HER2-positive MBC patients treated with THP were similar to those of patients in the CLEOPATRA trial. Much longer follow-up results would be warranted.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Pathological Complete Response to Neoadjuvant Trastuzumab and Pertuzumab Therapy is Dependent on HER2/CEP17 Ratio in HER2-Positive Breast Cancer
대한외과학회 학술대회 초록집
2018 .11
-
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
Cancer Research and Treatment
2016 .01
-
Nine months versus 12 months of adjuvant trastuzumab for patients with HER2-positive breast cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .12
-
Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study
Cancer Research and Treatment
2024 .07
-
Clinical Features of Male Breast Cancer: Experiences from Seven Institutions Over 20 Years
Cancer Research and Treatment
2016 .01
-
Clinical Implications According to Diagnostic Methods of Human Epidermal Growth Factor Receptor 2 Positivity in Breast Cancer: A Retrospective Study
Journal of Breast Disease
2018 .01
-
Prognostic Effect of Breast Cancer Subtypes in Metastatic Breast Cancer Patients
대한임상종양학회 학술대회지
2015 .02
-
Biomarkers That Predict an Unclear Benefit From Adjuvant Trastuzumab, Pertuzumab and Pembrolizumab When Those Same Drugs Were Given Neoadjuvantly
Journal of Breast Cancer
2023 .02
-
A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology
Cancer Research and Treatment
2016 .01
-
Adjuvant Trastuzumab Is Required in Human Epidermal Growth Factor Receptor 2-Positive Node-Negative Breast Cancer Patients Regardless of Tumour Size
Journal of Breast Cancer
2020 .01
-
Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
Yonsei Medical Journal
2023 .02
-
Safety Analysis of Adjuvant Chemotherapy with Docetaxel Administered with or without Anthracyclines to Early Stage Breast Cancer Patients: Combined Results from the Asia-Pacific Breast Initiatives I and II
Asian Pacific journal of cancer prevention : APJCP
2016 .01
-
Aromatase Inhibition and Capecitabine Combination as 1<sup>st</sup> or 2<sup>nd</sup> Line Treatment for Metastatic Breast Cancer - a Retrospective Analysis
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
A comparative study of the clinical characteristics and outcomes of hormone receptor positive, HER2 negative breast cancer patients over 65 years old and under 65 years old patients
대한임상종양학회 학술대회지
2020 .07
-
Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Chemotherapy-Induced Left Ventricular Dysfunction in Patients with Breast Cancer
Journal of Breast Cancer
2016 .01
-
A comparative study of the clinical characteristics of breast cancer patients less than 35 years old and older patients
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .06
-
Tryptophanyl-tRNA Synthetase Sensitizes Hormone Receptor-Positive Breast Cancer to Docetaxel-Based Chemotherapy
Journal of Breast Cancer
2020 .01
-
The Role of Primary Tumor Surgery in De Novo Metastatic Breast Cancer Patients
대한외과학회 학술대회 초록집
2016 .11
-
Benefits of Adjuvant Trastuzumab in HER2-Positive Breast Cancer with pT1a-bN0M0 : A Systematic Review and Meta-Analysis of Published literatures
대한외과학회 학술대회 초록집
2018 .11
이 논문의 저자 정보
최근 본 자료
댓글(0)
0